PDCD1 and non-small cell lung carcinoma: The above performance implies that for NSCLC patients with liver metastases, anti-angiogenesis treatment may serve as a promising scheme when they have failed with PD-1/PD-L1 inhibitors; however, further confirmation of this finding in larger scale studies is required.